{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T08:24:18.503539+00:00","company":{"ticker":"BHVN","cik":1935979,"company_name":"Biohaven Ltd."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"bc0aea2f855b876ab9beea815160f07d1772c930","cik":1935979,"ticker":"BHVN","company_name":"Biohaven Ltd.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2026","report_date":"2026-05-04","result_type":"reported_results","revenue_text":null},"claim":"Biohaven Ltd. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On May 4, 2026, Biohaven Ltd. (the \" Registrant \") issued a press release announcing its financial results for the first quarter ended March 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001935979-26-000044","anchor_url":"https://secwatch.observer/filing/0001935979-26-000044#claim-bc0aea2f855b876ab9beea815160f07d1772c930","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597926000044/0001935979-26-000044-index.htm"},{"fact_type":"earnings_release","fact_key":"b87eef9481b48f20d70fb995e79923d26a954fec","cik":1935979,"ticker":"BHVN","company_name":"Biohaven Ltd.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":null},"claim":"Biohaven Ltd. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a review of recent accomplishments and anticipated upcoming developments.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001935979-24-000047","anchor_url":"https://secwatch.observer/filing/0001935979-24-000047#claim-b87eef9481b48f20d70fb995e79923d26a954fec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597924000047/0001935979-24-000047-index.htm"}]}